We are delight­ed to have closed this financ­ing with such out­stand­ing investors.  This invest­ment acknowl­edges our lead­er­ship posi­tion as the first and only hand­held, objec­tive, FDA-cleared med­ical device for trau­mat­ic brain injury assess­ment. The financ­ing will not only help the com­pa­ny dri­ve com­mer­cial sales with­in var­i­ous mar­kets, but will also pro­vide cap­i­tal for research and devel­op­ment to broad­en our prod­uct port­fo­lio,” stat­ed Michael Singer, CEO of Brain­Scope.

Through­out our exten­sive dili­gence on Brain­Scope and poten­tial alter­na­tive approach­es for the triage of trau­mat­ic brain injury, we con­sis­tent­ly heard from clin­i­cians that the Brain­Scope prod­uct was a true break­through.  We are hap­py to be sup­port­ing this team,” stat­ed Cyn­thia Ringo, Senior Part­ner at DBL Part­ners.

Ms. Ringo will join BrainScope’s Board of Direc­tors.  Ms. Ringo cur­rently sits on the board of direc­tors of The Real­Real, Urban­sit­ter, Maiyet, RubyRib­bon, Siva Pow­er, and the Bay Area BUILD and is a mem­ber of Wom­en­Cor­po­rate­Di­rec­tors (WCD) Foun­da­tion.  She also served on the board of the Forum for Women Entre­pre­neurs from 2000 to 2004, and as Chair of the Board from 2001 through 2003. Ms. Ringo was for­merly a Man­ag­ing Direc­tor of Van­tage­Point Ven­ture Part­ners from 2002 to 2008. Pri­or to Van­tage­Point Ven­ture Part­ners, she served as the CEO of Cop­per­com, a next-gen­er­a­tion net­work switch­ing com­pany, from 1998 to 2001 and was the Chair­man of the Board from 2001 to 2002.

Brain­Scope One is an FDA-cleared med­ical device for rapid, objec­tive assess­ment of mild­ly pre­sent­ing adult head injured patients at the point of care for up to three days fol­low­ing injury, and is designed to help the clin­i­cian assess the full spec­trum of brain injury, includ­ing whether a patient has struc­tur­al brain injury vis­i­ble on CT, as well as whether a patient has func­tion­al brain injury, includ­ing con­cus­sion.  Brain­Scope One is avail­able to a cross-sec­tion of mar­ket seg­ments includ­ing urgent care clin­ics, occu­pa­tion­al health clin­ics, hos­pi­tal emer­gency rooms, uni­ver­si­ty and pro­fes­sion­al sports, and the U.S. mil­i­tary and gov­ern­ment.

Brain­Scope has been the recip­i­ent of sev­er­al pres­ti­gious awards over the past few months, includ­ing the Frost & Sul­li­van 2017 Best Prac­tices Award for New Prod­uct Inno­va­tion in the Trau­mat­ic Brain Injury Assess­ment Solu­tions Mar­ket, as well as a nom­i­na­tion for the 2017 Prix Galien USA Best Med­ical Tech­nol­o­gy, regard­ed as the equiv­a­lent of the Nobel Prize in med­ical tech­nol­o­gy research, with a win­ner to be cho­sen in Octo­ber.
About Brain­Scope
Brain­Scope Com­pa­ny, Inc. (“Brain­Scope”) is a med­ical neu­rotech­nol­o­gy com­pa­ny that is devel­op­ing a new gen­er­a­tion of hand­held, easy-to-use, non-inva­sive devices designed to aid med­ical pro­fes­sion­als in rapid­ly and objec­tive­ly assess­ing var­i­ous neu­ro­log­i­cal con­di­tions, begin­ning with trau­mat­ic brain injury (TBI), includ­ing con­cus­sion. The company’s first prod­uct intro­duced in 2017, Brain­Scope One (FDA cleared as Ahead 300), uses EEG-based tech­nol­o­gy that is non-inva­sive for mild­ly pre­sent­ing patients 18–85 years old and with­in 3 days after head injury. Brain­Scope One mea­sures and inter­prets brain elec­tri­cal activ­i­ty and a patient’s neu­rocog­ni­tive func­tion, cre­at­ing a pan­el of objec­tive data to help physi­cians make their clin­i­cal diag­no­sis. BrainScope’s tech­nol­o­gy plat­form inte­grates data­bas­es of thou­sands of brain­wave record­ings with advanced dig­i­tal sig­nal pro­cess­ing, sophis­ti­cat­ed algo­rithms, minia­tur­ized hard­ware and dis­pos­able head­set sen­sors, which are all cov­ered by an exten­sive intel­lec­tu­al prop­er­ty port­fo­lio of over 100 issued and pend­ing patents. Brain­Scope has received four FDA clear­ances and ISO 13485:2003 Cer­ti­fi­ca­tion. Brain­Scope has part­nered with the U.S. Depart­ment of Defense for the devel­op­ment of its TBI assess­ment tech­nol­o­gy, and was named both an orig­i­nal recip­i­ent and final awardee of the GE-NFL Head Health Chal­lenge I. For more infor­ma­tion, please vis­it www​.brain​scope​.com.